Genentech, Inc.
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
Published in Medical Letter on the CDC and FDA, June 21st, 2009
Genentech, Inc. announced results of a Phase III study (RIBBON 1) that showed AvastinŽ (bevacizumab) plus commonly used chemotherapies, including capecitabine and anthracycline-based therapies, increased the time women receiving first-line therapy for advanced HER2-negative breast cancer lived without the disease worsening (progression-free survival or PFS), compared to the chemotherapies alone. The safety profile of Avastin was consistent with previous experience, and no new safety signals for Avastin were observed in the study. The data will be presented on June 1, 2009, during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Columbia University's Mailman School of Public Health
New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia - SAGE Publications
FDA ignores critical information on home HIV tests - Abraxis BioScience, Inc.
New Study Results Published Compare ABRAXANEŽ to TaxotereŽ - Biologics
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis With Systemic Medications - Bird Flu
Study to Investigate AHCC and the Swine Flu Virus - Cancer Vaccines
Research from J. Bornstein and colleagues has provided new data on cancer vaccines - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
